Sio Gene Therapies Inc

Sio Gene Therapies — Axovant Sciences — Corporate Update (July 2018)

15 slides from Sio Gene Therapies's corporate update, Jul 9, 2018

  1. Slide 1: Forward Looking Statements

    FORWARD LOOKING STATEMENTS Statements made in this presentation contain forward-looking statements, including statements regarding Axovant’s plans to advance the development of its AXO-AAV-OPMD program and expand its pipeline with additional gene therapy products, Axovant’s expectations about timing

  2. Slide 2: Building a leader in innovative neurological therapies

    Building a leader in innovative neurological therapies Targeted approaches addressing the underlying biology of neurological conditions: Silence-and-Replace gene therapy platform across neurological indications Restoration of endogenous dopamine synthesis in Parkinson’s disease AXO-Lenti-PD: potenti

  3. Slide 3: Global license for AXO-AAV-OPMD Program and broader platform collaboration

    Global license for AXO-AAV-OPMD Program and broader platform collaboration Axovant granted worldwide rights to AXO-AAV-OPMD program and 5 investigational gene therapy products in neurological conditions Plan to initiate a placebo-controlled clinical study of AXO-AAV-OPMD gene therapy in oculopharyng

  4. Slide 4: Overview of oculopharyngeal muscular dystrophy (OPMD)

    Overview of oculopharyngeal muscular dystrophy (OPMD) Neuromuscular disorder caused by mutation in polyA-binding protein nuclear 1 (PABPN1) gene Primarily autosomal dominant inheritance Expansion of alanine-encoding trinucleotide repeats results in abnormally long polyalanine tract Mutated protein m

  5. Slide 5: Silence-and-Replace: a novel gene therapy strategy for genetic disorders

    Silence-and-Replace: a novel gene therapy strategy for genetic disorders Delivered in a single vector construct Silencing cannot discriminate between the mutant gene and the wild-type gene, therefore replacing a functional copy of the gene is essential in these conditions SILENCE mutant genes by usi

  6. Slide 6: Silence-and-Replace: one-time dose allows sustained silencing and gene expression

    Silence-and-Replace: one-time dose allows sustained silencing and gene expression Enzymatic cleavage of hairpin (DICER) siRNA Separates siRNA into single strands Cleavage of mutant mRNA Mutant gene silenced Protein Mutant gene X shRNA continually expressed siRNA-resistant functional mRNA AXO-AAV-OPM

  7. Slide 7: AXO-AAV-OPMD: Silence-and-Replace PABPN1

    AXO-AAV-OPMD: Silence-and-Replace PABPN1 GOALS OF THERAPY: Less troublesome dyskinesia Less OFF time More ON time Lower requirement for exogenous L-dopa Silences mutant PABPN1 gene and replaces with a functional copy Delivers sequences for shRNA-mediated knockdown of mutant PABPN1 Functional copy of

  8. Slide 8: 86% inhibition of PABPN1 in OPMD mouse model

    86% inhibition of PABPN1 in OPMD mouse model AXO-AAV-OPMD gene therapy reduces mutant PABPN1 and expresses functional copy PABPN1 knockdown 63% expression of PABPN1 transgene at highest dose in OPMD mouse model Functional PABPN1 expression

  9. Slide 9: AXO-AAV-OPMD gene therapy reverses intranuclear inclusions in mouse model

    AXO-AAV-OPMD gene therapy reverses intranuclear inclusions in mouse model Intranuclear inclusions measured 13 weeks after AXO-AAV-OPMD gene therapy ***P<0.001

  10. Slide 10: AXO-AAV-OPMD gene therapy restores muscle function and weight in a dose-dependent manner

    AXO-AAV-OPMD gene therapy restores muscle function and weight in a dose-dependent manner AXO-AAV-OPMD gene therapy normalized tibialis anterior muscle force and weight to wild-type levels at highest dose in mouse model Normal Dose AXO-AAV-OPMD Muscle Force *P<0.05, **P<0.01, ***P<0.001 Dose AXO-AAV-

  11. Slide 11: AXO-AAV-OPMD: anticipated clinical study design

    AXO-AAV-OPMD: anticipated clinical study design First patient expected to be dosed 2019 All dose cohorts will include matched placebo arm Delivery method: Direct injection into cricopharyngeal and pharyngeal muscles, and injection into the tongue for purposes of biopsy Key assessments: Safety and to

  12. Slide 12: AXO-AAV-OPMD: scalable, high-quality manufacturing process already in place

    AXO-AAV-OPMD: scalable, high-quality manufacturing process already in place AXO-AAV-OPMD will be produced with scalable, high-yield baculovirus based methodologies and purification processes to control COGS GMP-grade clinical material produced at a top-three, US-based gene therapy contract manufactu

  13. Slide 13: Financial terms of Benitec transaction

    Financial terms of Benitec transaction Upfront $10.0M in cash AXO-AAV-OPMD Program $67.5M development and regulatory milestones; $120.0M specified sales milestones; Benitec to receive 30% of net profits Each Additional Research Collaboration Program Development, regulatory, and sales milestones; Tie

  14. Slide 14: Key upcoming catalysts

    By YE:18 H2:18 2019 Key upcoming catalysts 2019 Initiate Phase 1/2 Study for AXO-Lenti-PD in advanced Parkinson’s disease Results from Nelotanserin Phase 2 Study of REM Sleep Behavior Disorder in LBD Initial data from AXO-Lenti-PD Phase 1/2 study Initiate clinical study for AXO-AAV-OPMD in oculophar

  15. Slide 15: Key upcoming catalysts

    Key upcoming catalysts Initiate Phase 1/2 Study for AXO- oy Lenti-PD in advanced Parkinson's disease Results from Nelotanserin Phase 2 A yw oO VA N T Study of REM Sleep Behavior A Disorder in LBD THE POWER OF AN OPEN MIND Initial data from AXO-Lenti-PD Phase 1/2 study Initiate clinical study for AXO

Axovant Sciences — Corporate Update (July 2018) on 6ix